DIAMEDICA THERAPEUTICS INC (DMAC)
CA25253X2077 - Common Stock
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the fourth quart...
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
DiaMedica Therapeutics names Masuoka as its chief medical officer (NASDAQ:DMAC)
DiaMedica Therapeutics appoints Lorianne Masuoka as its chief medical officer, bringing over 20 years of experience in the pharmaceutical industry.
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning.
Top Buys by Top Brass: Chief Business Officer Wambeke's $150K Bet on DMAC
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
Wednesday 6/28 Insider Buying Report: DMAC, VERA
DiaMedica Therapeutics up ~5%, reports directors and execs buying stock (NASDAQ:DMAC)
Clinical stage biopharmaceutical company, DiaMedica Therapeutics (DMAC) rose 4.5% to $4.40 on Monday late hours
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
FDA lifts clinical hold on DiaMedica's Phase 2/3 study for stroke drug (DMAC)
DiaMedica (DMAC) said the FDA has lifted a clinical hold on a Phase 2/3 study for its stroke drug candidate DM199 and that it has agreed to a $37.5M private placement of its stock.
DiaMedica Therapeutics Announces $37.5 Million Private Placement
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
SPAC Jupiter Wellness shareholders okay merger with EV maker Chijet (NASDAQ:JWAC)
SPAC Jupiter Wellness (JWAC) said its shareholders have approved a planned merger with Chinese EV maker Chijet Motor Company. Read more about the deal here.
Wednesday 4/12 Insider Buying Report: DMAC, COSM
Top Buys by Top Brass: Chief Business Officer Wambeke's $750K Bet on DMAC
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
